Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > REGULATORY
REGULATORY
- Health Minister Mitsui Hopes to Ban All Forms of Dispensing Point Services Including Those Using Credit Cards
October 9, 2012
- MHLW to Request Development of 5 Drugs/Indications Determined to Have Unmet Medical Needs
October 5, 2012
- Ministry-Wide Discussions on Generics Necessary: Parliamentary Secretary Umemura
October 4, 2012
- Senior Vice Minister Sakurai Calls for Industry-Growth Perspective on Long-Listed Drug Pricing
October 4, 2012
- MHLW Issues Notification for Precautions in Use of Methapain
October 4, 2012
- Minister of Health Mitsui Sees Need for Cross-Agency Efforts to Promote New Drug Development
October 4, 2012
- MHLW to Enhance Drug Review System to Eliminate Application Lag: PFSB Director Gen. Ebata
October 3, 2012
- Committee to Discuss Basic Policy for Improving Safety and Supply of Blood Products for Its Revision in FY2013
October 3, 2012
- MHLW Issues Improvement Order to Benesis Due to Tampering of Packaging Boxes after Permitting Shipment
October 2, 2012
- Pharmacist Mitsui Becomes Health Minister, Industry Hails Appointment
October 2, 2012
- MHLW Approves 26 Products Including Novartis’s Seebri
October 2, 2012
- Perpetuation of Premium for New Drug Development Will Depend on Convincing Data: HIB Director General Kikura
October 2, 2012
- Study Group Outlines Plan to Establish Palliative Care Centers at Designated Cancer Treatment Alliance Hospitals
October 1, 2012
- MHLW Reports Package Insert Revisions for Elplat
September 28, 2012
- Price Gap between Long-Listed Products, Generics Should Be Retained: Mr Chikazawa of MHLW
September 28, 2012
- MHLW Asks FPMAJ to Revise Precaution Section of Package Inserts for 13 APIs Including Diclofenac
September 28, 2012
- HSB to Make “Steady Efforts” Against Lifestyle Diseases: Director General Yajima
September 28, 2012
- Latest Proposal to Discuss Reference Pricing System Gets Cold Shoulder from CSIMC
September 26, 2012
- MHLW Reports 1 Dispensing Error Due to Name Similarity; Almarl Already Renamed
September 24, 2012
- MHLW Issues Notification to Prohibit Dispensing Point Services
September 21, 2012
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…